Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation

Immunity

Volumn 36, Issue 3, 2012, Pages 491-501

  Shan, Liang ^a   Deng, Kai ^a   Shroff, Neeta S ^a   Durand, Christine M ^a   Rabi, S Alireza ^a   Yang, Hung Chih ^b   Zhang, Hao ^c   Margolick, Joseph B ^c   Blankson, Joel N ^a   Siliciano, Robert F ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE CARRIER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOSTIMULATION; IN VITRO STUDY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS LATENCY; VIRUS REACTIVATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; CYTOPATHOGENIC EFFECT, VIRAL; CYTOTOXICITY, IMMUNOLOGIC; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; PROVIRUSES; T-LYMPHOCYTES, CYTOTOXIC; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84863337769     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2012.01.014     Document Type: Article

References (60)

1. Archin N.M., Eron J.J., Palmer S., Hartmann-Duff A., Martinson J.A., Wiegand A., Bandarenko N., Schmitz J.L., Bosch R.J., Landay A.L., et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008, 22:1131-1135.
2. Archin N.M., Espeseth A., Parker D., Cheema M., Hazuda D., Margolis D.M. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 2009, 25:207-212.
3. Archin N.M., Cheema M., Parker D., Wiegand A., Bosch R.J., Coffin J.M., Eron J., Cohen M., Margolis D.M. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS ONE 2010, 5:e9390.
4. Bolton D.L., Hahn B.I., Park E.A., Lehnhoff L.L., Hornung F., Lenardo M.J. Death of CD4(+) T-cell lines caused by human immunodeficiency virus type 1 does not depend on caspases or apoptosis. J. Virol. 2002, 76:5094-5107.
5. Borrow P., Lewicki H., Wei X., Horwitz M.S., Peffer N., Meyers H., Nelson J.A., Gairin J.E., Hahn B.H., Oldstone M.B., Shaw G.M. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 1997, 3:205-211.
6. Bosque A., Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2009, 113:58-65.
7. Brooks D.G., Hamer D.H., Arlen P.A., Gao L., Bristol G., Kitchen C.M., Berger E.A., Zack J.A. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003, 19:413-423.
8. Chun T.W., Finzi D., Margolick J., Chadwick K., Schwartz D., Siliciano R.F. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1995, 1:1284-1290.
9. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
10. Chun T.W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A., Baseler M., Lloyd A.L., Nowak M.A., Fauci A.S. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 1997, 94:13193-13197.
11. Chun T.W., Engel D., Mizell S.B., Hallahan C.W., Fischette M., Park S., Davey R.T., Dybul M., Kovacs J.A., Metcalf J.A., et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 1999, 5:651-655.
12. Chun T.W., Justement J.S., Lempicki R.A., Yang J., Dennis G., Hallahan C.W., Sanford C., Pandya P., Liu S., McLaughlin M., et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc. Natl. Acad. Sci. USA 2003, 100:1908-1913.
13. Contreras X., Schweneker M., Chen C.S., McCune J.M., Deeks S.G., Martin J., Peterlin B.M. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 2009, 284:6782-6789.
14. Deeks S.G., Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27:406-416.
15. Doitsh G., Cavrois M., Lassen K.G., Zepeda O., Yang Z., Santiago M.L., Hebbeler A.M., Greene W.C. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010, 143:789-801.
16. Edelstein L.C., Micheva-Viteva S., Phelan B.D., Dougherty J.P. Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res. Hum. Retroviruses 2009, 25:883-887.
17. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
18. Gandhi R.T., Walker B.D. Immunologic control of HIV-1. Annu. Rev. Med. 2002, 53:149-172.
19. Goping I.S., Sawchuk T., Rieger A., Shostak I., Bleackley R.C. Cytotoxic T lymphocytes overcome Bcl-2 inhibition: target cells contribute to their own demise. Blood 2008, 111:2142-2151.
20. Hermankova M., Siliciano J.D., Zhou Y., Monie D., Chadwick K., Margolick J.B., Quinn T.C., Siliciano R.F. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J. Virol. 2003, 77:7383-7392.
21. Hersperger A.R., Pereyra F., Nason M., Demers K., Sheth P., Shin L.Y., Kovacs C.M., Rodriguez B., Sieg S.F., Teixeira-Johnson L., et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010, 6:e1000917.
22. Hersperger A.R., Migueles S.A., Betts M.R., Connors M. Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr. Opin. HIV AIDS 2011, 6:169-173.
23. Jordan A., Bisgrove D., Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 2003, 22:1868-1877.
24. Kalams S.A., Goulder P.J., Shea A.K., Jones N.G., Trocha A.K., Ogg G.S., Walker B.D. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 1999, 73:6721-6728.
25. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 1994, 68:4650-4655.
26. Kulkosky J., Nunnari G., Otero M., Calarota S., Dornadula G., Zhang H., Malin A., Sullivan J., Xu Y., DeSimone J., et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 2002, 186:1403-1411.
27. Lehrman G., Hogue I.B., Palmer S., Jennings C., Spina C.A., Wiegand A., Landay A.L., Coombs R.W., Richman D.D., Mellors J.W., et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366:549-555.
28. Marini A., Harper J.M., Romerio F. An in vitro system to model the establishment and reactivation of HIV-1 latency. J. Immunol. 2008, 181:7713-7720.
29. Migueles S.A., Osborne C.M., Royce C., Compton A.A., Joshi R.P., Weeks K.A., Rood J.E., Berkley A.M., Sacha J.B., Cogliano-Shutta N.A., et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008, 29:1009-1021.
30. Migueles S.A., Weeks K.A., Nou E., Berkley A.M., Rood J.E., Osborne C.M., Hallahan C.W., Cogliano-Shutta N.A., Metcalf J.A., McLaughlin M., et al. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J. Virol. 2009, 83:11876-11889.
31. O'Connell K.A., Bailey J.R., Blankson J.N. Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol. Sci. 2009, 30:631-637.
32. Packard B.Z., Telford W.G., Komoriya A., Henkart P.A. Granzyme B activity in target cells detects attack by cytotoxic lymphocytes. J. Immunol. 2007, 179:3812-3820.
33. Prins J.M., Jurriaans S., van Praag R.M., Blaak H., van Rij R., Schellekens P.T., ten Berge I.J., Yong S.L., Fox C.H., Roos M.T., et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999, 13:2405-2410.
34. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
35. Roshal M., Zhu Y., Planelles V. Apoptosis in AIDS. Apoptosis 2001, 6:103-116.
36. Sáez-Cirión A., Lacabaratz C., Lambotte O., Versmisse P., Urrutia A., Boufassa F., Barré-Sinoussi F., Delfraissy J.F., Sinet M., Pancino G., Venet A. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. USA 2007, 104:6776-6781. Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group.
37. Sagot-Lerolle N., Lamine A., Chaix M.L., Boufassa F., Aboulker J.P., Costagliola D., Goujard C., Pallier C., Delfraissy J.F., Lambotte O. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008, 22:1125-1129. ANRS EP39 study.
38. Sahu G.K., Lee K., Ji J., Braciale V., Baron S., Cloyd M.W. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology 2006, 355:127-137.
39. Sakai K., Dimas J., Lenardo M.J. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc. Natl. Acad. Sci. USA 2006, 103:3369-3374.
40. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B.J., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
41. Shedlock D.J., Hwang D., Choo A.Y., Chung C.W., Muthumani K., Weiner D.B. HIV-1 viral genes and mitochondrial apoptosis. Apoptosis 2008, 13:1088-1099.
42. Siliciano J.D., Siliciano R.F. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol. Biol. 2005, 304:3-15.
43. Siliciano J.D., Kajdas J., Finzi D., Quinn T.C., Chadwick K., Margolick J.B., Kovacs C., Gange S.J., Siliciano R.F. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 2003, 9:727-728.
44. Siliciano J.D., Lai J., Callender M., Pitt E., Zhang H., Margolick J.B., Gallant J.E., Cofrancesco J., Moore R.D., Gange S.J., Siliciano R.F. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 2007, 195:833-836.
45. Steel A., Clark S., Teo I., Shaunak S., Nelson M., Gazzard B., Kelleher P. No change to HIV-1 latency with valproate therapy. AIDS 2006, 20:1681-1682.
46. Stellbrink H.J., van Lunzen J., Westby M., O'Sullivan E., Schneider C., Adam A., Weitner L., Kuhlmann B., Hoffmann C., Fenske S., et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002, 16:1479-1487.
47. Stockinger B., Bourgeois C., Kassiotis G. CD4+ memory T cells: functional differentiation and homeostasis. Immunol. Rev. 2006, 211:39-48.
48. Strain M.C., Günthard H.F., Havlir D.V., Ignacio C.C., Smith D.M., Leigh-Brown A.J., Macaranas T.R., Lam R.Y., Daly O.A., Fischer M., et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc. Natl. Acad. Sci. USA 2003, 100:4819-4824.
49. Surh C.D., Boyman O., Purton J.F., Sprent J. Homeostasis of memory T cells. Immunol. Rev. 2006, 211:154-163.
50. Taylor J.J., Jenkins M.K. CD4+ memory T cell survival. Curr. Opin. Immunol. 2011, 23:319-323.
51. Tyagi M., Pearson R.J., Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 2010, 84:6425-6437.
52. van Leeuwen E.M., Sprent J., Surh C.D. Generation and maintenance of memory CD4(+) T Cells. Curr. Opin. Immunol. 2009, 21:167-172.
53. van Praag R.M., Prins J.M., Roos M.T., Schellekens P.T., Ten Berge I.J., Yong S.L., Schuitemaker H., Eerenberg A.J., Jurriaans S., de Wolf F., et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J. Clin. Immunol. 2001, 21:218-226.
54. Walker B.D., Chakrabarti S., Moss B., Paradis T.J., Flynn T., Durno A.G., Blumberg R.S., Kaplan J.C., Hirsch M.S., Schooley R.T. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987, 328:345-348.
55. Wong J.K., Hezareh M., Günthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
56. Xing S., Bullen C.K., Shroff N.S., Shan L., Yang H.C., Manucci J.L., Bhat S., Zhang H., Margolick J.B., Quinn T.C., et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J. Virol. 2011, 85:6060-6064.
57. Yang H.C., Xing S., Shan L., O'Connell K., Dinoso J., Shen A., Zhou Y., Shrum C.K., Han Y., Liu J.O., et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 2009, 119:3473-3486.
58. Ylisastigui L., Archin N.M., Lehrman G., Bosch R.J., Margolis D.M. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004, 18:1101-1108.
59. Zhang D., Beresford P.J., Greenberg A.H., Lieberman J. Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc. Natl. Acad. Sci. USA 2001, 98:5746-5751.
60. Zhou Y., Shen L., Yang H.C., Siliciano R.F. Preferential cytolysis of peripheral memory CD4+ T cells by in vitro X4-tropic human immunodeficiency virus type 1 infection before the completion of reverse transcription. J. Virol. 2008, 82:9154-9163.